Literature DB >> 27807357

Cancer metabolism pipeline breaks new ground.

Asher Mullard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27807357     DOI： 10.1038/nrd.2016.223

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  16 in total

Review 1.  Role of PKM2 in directing the metabolic fate of glucose in cancer: a potential therapeutic target.

Authors:  Gustav van Niekerk; Anna-Mart Engelbrecht
Journal:  Cell Oncol (Dordr)       Date:  2018-05-24       Impact factor: 6.730

Review 2.  Targeting amino acid metabolism for cancer therapy.

Authors:  Michael J Lukey; William P Katt; Richard A Cerione
Journal:  Drug Discov Today       Date:  2016-12-14       Impact factor: 7.851

Review 3.  Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health.

Authors:  Feixiong Cheng; Han Liang; Atul J Butte; Charis Eng; Ruth Nussinov
Journal:  Pharmacol Rev       Date:  2018-12-13       Impact factor: 25.468

Review 4.  Causes, consequences, and therapy of tumors acidosis.

Authors:  Smitha R Pillai; Mehdi Damaghi; Yoshinori Marunaka; Enrico Pierluigi Spugnini; Stefano Fais; Robert J Gillies
Journal:  Cancer Metastasis Rev       Date:  2019-06       Impact factor: 9.264

5.  PYCR1 regulates glutamine metabolism to construct an immunosuppressive microenvironment for the progression of clear cell renal cell carcinoma.

Authors:  Xiyi Wei; Xi Zhang; Shuai Wang; Yichun Wang; Chengjian Ji; Liangyu Yao; Ninghong Song
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

6.  TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress.

Authors:  Hiroyuki Ueno; Seiji Miyahara; Takuya Hoshino; Wakako Yano; Sayaka Tsukioka; Takamasa Suzuki; Shoki Hara; Yoshio Ogino; Khoon Tee Chong; Tatsuya Suzuki; Shingo Tsuji; Hikaru Itadani; Ikuo Yamamiya; Yoshihiro Otsu; Satoshi Ito; Toshiya Yonekura; Miki Terasaka; Nozomu Tanaka
Journal:  Commun Biol       Date:  2022-06-09

Review 7.  Regulatory pathways and drugs associated with ferroptosis in tumors.

Authors:  Dan Wang; Le Tang; Yijie Zhang; Guili Ge; Xianjie Jiang; Yongzhen Mo; Pan Wu; Xiangying Deng; Lvyuan Li; Sicheng Zuo; Qijia Yan; Shanshan Zhang; Fuyan Wang; Lei Shi; Xiayu Li; Bo Xiang; Ming Zhou; Qianjin Liao; Can Guo; Zhaoyang Zeng; Wei Xiong; Zhaojian Gong
Journal:  Cell Death Dis       Date:  2022-06-10       Impact factor: 9.685

Review 8.  Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance.

Authors:  Fang Wei; Dan Wang; Junyuan Wei; Niwen Tang; Le Tang; Fang Xiong; Can Guo; Ming Zhou; Xiaoling Li; Guiyuan Li; Wei Xiong; Shanshan Zhang; Zhaoyang Zeng
Journal:  Cell Mol Life Sci       Date:  2020-07-11       Impact factor: 9.261

Review 9.  Inhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy.

Authors:  Yung Lyou; Amber N Habowski; George T Chen; Marian L Waterman
Journal:  Br J Pharmacol       Date:  2017-08-24       Impact factor: 8.739

10.  IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors.

Authors:  Remco J Molenaar; Tomas Radivoyevitch; Yasunobu Nagata; Mohammed Khurshed; Bartolomiej Przychodzen; Hideki Makishima; Mingjiang Xu; Fonnet E Bleeker; Johanna W Wilmink; Hetty E Carraway; Sudipto Mukherjee; Mikkael A Sekeres; Cornelis J F van Noorden; Jaroslaw P Maciejewski
Journal:  Clin Cancer Res       Date:  2018-01-16       Impact factor: 13.801
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.